Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $9.20.

Several equities research analysts recently commented on PYXS shares. HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Pyxis Oncology in a research note on Wednesday, March 19th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th.

Pyxis Oncology Price Performance

NASDAQ PYXS traded down $0.10 on Friday, reaching $1.06. The company had a trading volume of 370,758 shares, compared to its average volume of 740,190. The firm has a market cap of $64.98 million, a price-to-earnings ratio of -1.02 and a beta of 1.11. Pyxis Oncology has a fifty-two week low of $0.99 and a fifty-two week high of $6.18. The business has a 50 day moving average of $1.31 and a two-hundred day moving average of $2.31.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01. The company had revenue of $16.15 million for the quarter. As a group, research analysts predict that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of Pyxis Oncology

Several institutional investors have recently made changes to their positions in PYXS. Millennium Management LLC boosted its holdings in Pyxis Oncology by 53.8% during the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock worth $4,650,000 after purchasing an additional 1,043,228 shares during the last quarter. Geode Capital Management LLC boosted its position in Pyxis Oncology by 5.5% during the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company's stock worth $3,982,000 after purchasing an additional 57,016 shares during the period. State Street Corp grew its stake in Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company's stock valued at $3,491,000 after buying an additional 208,344 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Pyxis Oncology by 57.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock valued at $939,000 after purchasing an additional 219,100 shares during the period. Finally, Ridgeback Capital Investments L.P. bought a new position in shares of Pyxis Oncology in the fourth quarter valued at approximately $560,000. Institutional investors own 39.09% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.